The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis

European Respiratory Journal

Volumn 20, Issue 4, 2002, Pages 975-981

  Meert, A P ^a   Martin, B ^a   Delmotte, P ^a   Berghmans, T ^a   Lafitte, J J ^a   Mascaux, C ^a   Paesmans, M ^a   Steels, E ^a   Verdebout, J M ^a   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Epidermal growth factor; Lung cancer; Receptor; Systematic review

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 18644377457     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00296502     Document Type: Article

References (37)

1. Paesmans M, Sculier JP. Prognosis factors in lung cancer (Facteurs pronostiques des cancers bronchopulmonaires). Arnette 1998; 239-247.
2. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Oncol Clin North Am 1997; 11: 409-434.
3. Kanters SD, Lammers JW, Voest EE. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 1995; 8: 1389-1397.
4. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992; 4: 1-24.
5. de Jong JS, van Diest PJ, van d Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998; 184: 53-57.
6. Steels E, Paesmans M, Berghmans T, et al. Role of p53 on the survival of patients with lung cancer as assessed by systematic review of the literature. Eur Respir J 2001; 18: 705-719.
7. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
8. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
9. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6: 2349-2355.
10. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and her2-neu mRNA expression in non small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
11. Giatromanolaki A, Gorgoulis V, Chetty R, et al. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 1996; 16: 987-993.
12. Fu X-L, Zhu X-Z, Shi D-R, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23: 143-152.
13. D'Amico TA, Massey M, Herndon JE, Moore M-B, Harpole DH. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thor Cardiovasc Surg 1999; 117: 736-743.
14. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncology 1997; 15: 2858-2865.
15. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50: 7077-7080.
16. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Rep 2000; 7: 603-607.
17. Pfeiffer P, Nexo E, Bentzen SM, Clausen PP, Andersen K, Rose C. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 1998; 78: 96-99.
18. Dazzi H, Hasleton PS, Thatcher N, et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 1989; 59: 746-749.
19. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 1997; 74: 565-570.
20. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998; 77: 663-669.
21. Fontanini G, De Laurentis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4: 241-249.
22. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
23. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68: 162-165.
24. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998; 157: 1093-1097.
25. Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992; 12: 11-20.
26. Volm M, Drings P, Wodrich W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 1993; 119: 507-510.
27. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-2385.
28. Koukourakis MI, Giatromanolaki A, Guddo F, et al. c-erbB-2 and episialin challenges host immune response by HLA class I expression in human non-small-cell lung cancer. J Immunother 2000; 23: 104-114.
29. Tateishi M, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surgical Oncol 1994; 3: 109-113.
30. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995; 55: 1365-1372.
31. Meert AP, Berghmans T, Branle F, et al. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res 1999; 19: 4379-4390.
32. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-329.
33. Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-1903.
34. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-422.
35. Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106: 485-488.
36. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1: 5.
37. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-484.